| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ilkay Orhan, Fatma Tosun, Bilge Sene. Coumarin, anthroquinone and stilbene derivatives with anticholinesterase activity. Zeitschrift fur Naturforschung. C, Journal of biosciences. vol 63. issue 5-6. 2008-08-26. PMID:18669022. |
acetylcholinesterase (ache) and butyrylcholinesterase (bche) are the key enzymes in pathogenesis of alzheimer's disease (ad), which is characterized by a deficit in central cholinergic transmission. |
2008-08-26 |
2023-08-12 |
Not clear |
| A Kadir, T Darreh-Shori, O Almkvist, A Wall, M Grut, B Strandberg, A Ringheim, B Eriksson, G Blomquist, B Långström, A Nordber. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiology of aging. vol 29. issue 8. 2008-08-21. PMID:17379359. |
the effect of galantamine treatment on cortical acetylcholinesterase (ache) activity and nicotinic receptor binding was investigated by positron emission tomography (pet) in 18 patients with mild alzheimer's disease (ad) in relation to galantamine concentration and the patients' cognitive performances. |
2008-08-21 |
2023-08-12 |
Not clear |
| Mohammad A Kamal, Peter Klein, Weiming Luo, Yazhou Li, Harold W Holloway, David Tweedie, Nigel H Grei. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine. Neurochemical research. vol 33. issue 5. 2008-08-11. PMID:17985237. |
cholinergic loss is the single most replicated neurotransmitter deficiency in alzheimer's disease (ad) and has led to the use of acetylcholinesterase inhibitors (ache-is) and unselective cholinesterase inhibitors (che-is) as the mainstay of treatment. |
2008-08-11 |
2023-08-12 |
human |
| Minoru Fujiki, Takeshi Kubo, Tohru Kamida, Kenji Sugita, Takamitsu Hikawa, Tatsuya Abe, Keisuke Ishii, Hidenori Kobayash. Neuroprotective and antiamnesic effect of donepezil, a nicotinic acetylcholine-receptor activator, on rats with concussive mild traumatic brain injury. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. vol 15. issue 7. 2008-08-11. PMID:18407501. |
donepezil is an acetylcholinesterase inhibitor that is used to treat alzheimer's disease. |
2008-08-11 |
2023-08-12 |
rat |
| Strahil Berkov, Jaume Bastida, Francesc Viladomat, Carles Codin. Analysis of galanthamine-type alkaloids by capillary gas chromatography-mass spectrometry in plants. Phytochemical analysis : PCA. vol 19. issue 4. 2008-08-11. PMID:18438759. |
galanthamine, an acetylcholinesterase inhibitor used for the treatment of alzheimer's disease, and galanthamine-type alkaloids are synthesised in different plants of the family amaryllidaceae. |
2008-08-11 |
2023-08-12 |
Not clear |
| Miki Tsujita, Shigeki Sakuraba, Junya Kuribayashi, Yuki Hosokawa, Eiki Hatori, Yasumasa Okada, Masanori Kashiwagi, Junzo Takeda, Shun-Ichi Kuwan. Antagonism of morphine-induced central respiratory depression by donepezil in the anesthetized rabbit. Biological research. vol 40. issue 3. 2008-08-07. PMID:18449461. |
we therefore asked whether donepezil (a long-acting acetylcholinesterase inhibitor used in the treatment of alzheimer's disease) can antagonize morphine-induced respiratory depression. |
2008-08-07 |
2023-08-12 |
rabbit |
| Hai Yan Zhang, Han Yan, Xi Can Tan. Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase. Cellular and molecular neurobiology. vol 28. issue 2. 2008-07-30. PMID:17657601. |
the use of acetylcholinesterase inhibitors to decrease the breakdown of the neurotransmitter acetylcholine has been the main symptomatic therapy for mild to moderate alzheimer's patients, though the etiology of alzheimer's disease remains unclear and seems to involve multiple factors. |
2008-07-30 |
2023-08-12 |
Not clear |
| Hai Yan Zhang, Han Yan, Xi Can Tan. Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase. Cellular and molecular neurobiology. vol 28. issue 2. 2008-07-30. PMID:17657601. |
further evidence has indicated that some of these acetylcholinesterase inhibitors also have non-cholinergic functions on the pathogenesis of alzheimer's disease including the formation and deposition of beta-amyloid. |
2008-07-30 |
2023-08-12 |
Not clear |
| Hai Yan Zhang, Han Yan, Xi Can Tan. Non-cholinergic effects of huperzine A: beyond inhibition of acetylcholinesterase. Cellular and molecular neurobiology. vol 28. issue 2. 2008-07-30. PMID:17657601. |
huperzine a, a potent and reversible inhibitor of acetylcholinesterase that was initially isolated from a chinese herb, has been found to improve cognitive deficits in a broad range of animal models and has been used for alzheimer's disease treatment in china. |
2008-07-30 |
2023-08-12 |
Not clear |
| Hiroko Tsunekawa, Yukihiro Noda, Akihiro Mouri, Fumio Yoneda, Toshitaka Nabeshim. Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). Behavioural brain research. vol 190. issue 2. 2008-07-30. PMID:18420288. |
selegiline, an irreversible inhibitor of monoamine oxidase b used in the treatment of parkinson's disease, has been demonstrated to have a potential cognition-improving effect in patients with alzheimer's disease (ad) undergoing treatment with an acetylcholinesterase inhibitor donepezil. |
2008-07-30 |
2023-08-12 |
mouse |
| Naoko Kaneko, Kazunobu Sawamot. [Neuronal migration in the adult brain]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 28. issue 2. 2008-07-24. PMID:18516984. |
however, we found that their survival could be promoted by the long-term administration of donepezil, an acetylcholinesterase inhibitor that is widely used for the treatment of alzheimer's disease. |
2008-07-24 |
2023-08-12 |
mouse |
| Katsutoshi Nakahata, Hiroyuki Kinoshita, Keiko Hama-Tomioka, Yuko Ishida, Naoyuki Matsuda, Noboru Hatakeyama, Masanori Haba, Toshikazu Kondo, Yoshio Hatan. Cholinesterase inhibitor donepezil dilates cerebral parenchymal arterioles via the activation of neuronal nitric oxide synthase. Anesthesiology. vol 109. issue 1. 2008-07-21. PMID:18580182. |
an acetylcholinesterase inhibitor donepezil currently is used to treat patients with alzheimer disease. |
2008-07-21 |
2023-08-12 |
Not clear |
| Nibaldo C Inestrosa, Margarita C Dinamarca, Alejandra Alvare. Amyloid-cholinesterase interactions. Implications for Alzheimer's disease. The FEBS journal. vol 275. issue 4. 2008-06-17. PMID:18205831. |
the fact that acetylcholinesterase accelerates amyloid formation and the effect is sensitive to peripherical anionic site blockers of the enzyme, suggests that specific and new acetylcholinesterase inhibitors may well provide an attractive possibility for treating alzheimer's disease. |
2008-06-17 |
2023-08-12 |
Not clear |
| Susan A Greenfield, Martina Zimmermann, Cherie E Bon. Non-hydrolytic functions of acetylcholinesterase. The significance of C-terminal peptides. The FEBS journal. vol 275. issue 4. 2008-06-17. PMID:18205834. |
more specifically, c-terminal sequences of acetylcholinesterase may act as signalling molecules in key brain regions characteristically vulnerable to alzheimer's, parkinson's and motor neuron disease. |
2008-06-17 |
2023-08-12 |
Not clear |
| Seong Hye Choi, Sang Yun Kim, Hae Ri Na, Byung-Kun Kim, Dong Won Yang, Jay C Kwon, Mee Young Par. Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease. Dementia and geriatric cognitive disorders. vol 25. issue 5. 2008-06-17. PMID:18401173. |
the possible influence of apolipoprotein e (apoe) genotype on the response to acetylcholinesterase inhibitor therapy in patients with alzheimer's disease (ad) remains a matter of controversy. |
2008-06-17 |
2023-08-12 |
Not clear |
| Scott D Bembenek, John M Keith, Michael A Letavic, Richard Apodaca, Ann J Barbier, Lisa Dvorak, Leah Aluisio, Kirsten L Miller, Timothy W Lovenberg, Nicholas I Carruther. Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling. Bioorganic & medicinal chemistry. vol 16. issue 6. 2008-06-13. PMID:18249544. |
currently, the only clinically effective treatment for alzheimer's disease (ad) is the use of acetylcholinesterase (ache) inhibitors. |
2008-06-13 |
2023-08-12 |
Not clear |
| Min Wang, Ji-Quan Wang, Mingzhang Gao, Qi-Huang Zhen. Facile synthesis of new carbon-11 labeled conformationally restricted rivastigmine analogues as potential PET agents for imaging AChE and BChE enzymes. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine. vol 66. issue 4. 2008-06-10. PMID:18155915. |
rivastigmine is a newer-generation inhibitor with a dual inhibitory action on both acetylcholinesterase (ache) and butyrylcholinesterase (bche) enzymes, and is used for the treatment of ache- and bche-related diseases such as brain alzheimer's disease and cardiovascular disease. |
2008-06-10 |
2023-08-12 |
Not clear |
| Sarah Lyle, Moni Grizzell, Sasi Willmott, Susan Benbow, Michael Clark, David Jolle. Treatment of a whole population sample of Alzheimer's disease with donepezil over a 4-year period: lessons learned. Dementia and geriatric cognitive disorders. vol 25. issue 3. 2008-05-20. PMID:18230972. |
in the uk it is recommended that acetylcholinesterase inhibitors be restricted to patients with moderate alzheimer's disease, and progress monitored within specialist clinics. |
2008-05-20 |
2023-08-12 |
Not clear |
| T Leyhe, Elke Stransky, G W Eschweiler, G Buchkremer, C Lask. Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer's disease. European archives of psychiatry and clinical neuroscience. vol 258. issue 2. 2008-05-15. PMID:17990049. |
alzheimer's disease (ad) can be treated with inhibitors of the enzyme acetylcholinesterase (ache). |
2008-05-15 |
2023-08-12 |
Not clear |
| Saviana Di Giovanni, Aline Borloz, Aurélie Urbain, Andrew Marston, Kurt Hostettmann, Pierre-Alain Carrupt, Marianne Reis. In vitro screening assays to identify natural or synthetic acetylcholinesterase inhibitors: thin layer chromatography versus microplate methods. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. vol 33. issue 2. 2008-04-24. PMID:18082383. |
acetylcholinesterase inhibitors (achei) are currently still the best available pharmacotherapy for alzheimer patients. |
2008-04-24 |
2023-08-12 |
Not clear |